- MBX Biosciences, Inc.
MBX Biosciences, Inc.
Website
Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$16.00
10,200,000
Positive
High
17.92%
Offering Team
Deal Managers
- J P Morgan Chase
- Jefferies
- Guggenheim
Lawyers
- Goodwin Procter LLP
Auditors
- Ernst & Young LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEP™, platform to overcome the key limitations of unmodified and modified peptide therapies More
Deal Tracker
Investors
Filing
23 Aug, 2024Offer
13 Sep, 2024Look Ahead
Lock Up Expiry
13 Mar, 2025Earning
Nov 1, 2018IPO Terms
Offer Price | $16.00 |
Offer Size | 10M |